1-4 of 4
Louis Kwong
Close
Sort by
Journal Articles

Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4

Alexander GG Turpie, MD, Kenneth A. Bauer, MD, Bruce Davidson, MD, Michael Gent, MD, Louis Kwong, MD, Michael Rud Lassen, MD, Fred Cushner, MD, Paul Lotke, MD, Scott D. Berkowitz, MD, FACP, Tiemo Joerg Bandel, Frank Misselwitz, MD, William Fisher, MD
Journal: Blood
Blood (2008) 112 (11): 35.
https://doi.org/10.1182/blood.V112.11.35.35
Published: 2008
Journal Articles

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Replacement: Impact on Healthcare Costs Based on the RECORD4 Study.

Louis Kwong, Nishan Sengupta, Michael Lees
Journal: Blood
Blood (2008) 112 (11): 1289.
https://doi.org/10.1182/blood.V112.11.1289.1289
Published: 2008
Journal Articles

Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients?

Louis Kwong, Alexander Diamantopoulos, Fiona Forster, Nishan Sengupta, Michael Lees
Journal: Blood
Blood (2008) 112 (11): 1290.
https://doi.org/10.1182/blood.V112.11.1290.1290
Published: 2008
Journal Articles

Rivaroxaban for Prevention of Venous Thromboembolism after Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study.

Louis Kwong, MD, Michael Lees, M.COM, Nishan Sengupta, PHD
Journal: Blood
Blood (2007) 110 (11): 1874.
https://doi.org/10.1182/blood.V110.11.1874.1874
Published: 2007